AXON NEUROSCIENCE SE
- Country
- 🇨🇾Cyprus
- Ownership
- Subsidiary
- Established
- 1999-04-06
- Employees
- 101
- Market Cap
- -
Clinical Trials
10
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia
- Conditions
- Primary Progressive Nonfluent Aphasia
- Interventions
- Drug: AADvac1 40 µgDrug: AADvac1 160 µg
- First Posted Date
- 2017-06-05
- Last Posted Date
- 2019-11-14
- Lead Sponsor
- Axon Neuroscience SE
- Target Recruit Count
- 33
- Registration Number
- NCT03174886
- Locations
- 🇩🇪
Universitätsmedizin Göttingen, Klinik für Psychiatrie und Psychotherapie, Göttingen, Germany
🇩🇪Klinikum Rechts der Isar der TU München, Klinik und Poliklinik für Psychiatrie und Psychotherapie, München, Germany
🇩🇪Universitätsklinikum Ulm, Ulm, Germany
24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Interventions
- Biological: AADvac1Drug: Placebo
- First Posted Date
- 2015-10-19
- Last Posted Date
- 2019-11-14
- Lead Sponsor
- Axon Neuroscience SE
- Target Recruit Count
- 208
- Registration Number
- NCT02579252
- Locations
- 🇦🇹
Ordination Dr. Bancher, Horn, Niederosterreich, Austria
🇦🇹Universitätsklinik für Neurologie, Graz, Steiermark, Austria
🇦🇹Abteilung Psychiatrie und Psychotherapie, LKH Hall, Hall in Tirol, Tirol, Austria
18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease
- First Posted Date
- 2014-01-09
- Last Posted Date
- 2017-03-17
- Lead Sponsor
- Axon Neuroscience SE
- Target Recruit Count
- 25
- Registration Number
- NCT02031198
- Locations
- 🇦🇹
Medizinische Universitat Graz, Graz, Steiermark, Austria
🇦🇹Univeristätsklinik für Neurologie, PMU, Christian-Doppler Klinik, Salzburg, Austria
🇦🇹Medizinische Universitat Wien, Wien, Austria
Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease
- Conditions
- Alzheimer Disease
- First Posted Date
- 2013-05-09
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Axon Neuroscience SE
- Target Recruit Count
- 30
- Registration Number
- NCT01850238
- Locations
- 🇦🇹
Medizinische Universitat Graz, Graz, Steiermark, Austria
🇦🇹Univeristätsklinik für Neurologie, PMU, Christian-Doppler Klinik, Salzburg, Austria
🇦🇹Medizinische Universitat Wien, Wien, Austria